Cargando…

SLE clinical trials: impact of missing data on estimating treatment effects

OBJECTIVE: A common problem in clinical trials is missing data due to participant dropout and loss to follow-up, an issue which continues to receive considerable attention in the clinical research community. Our objective was to examine and compare current and alternative methods for handling missin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mimi, Merrill, Joan T, Wang, Cuiling, Viswanathan, Shankar, Kalunian, Ken, Hanrahan, Leslie, Izmirly, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784820/
https://www.ncbi.nlm.nih.gov/pubmed/31649825
http://dx.doi.org/10.1136/lupus-2019-000348
_version_ 1783457812292042752
author Kim, Mimi
Merrill, Joan T
Wang, Cuiling
Viswanathan, Shankar
Kalunian, Ken
Hanrahan, Leslie
Izmirly, Peter
author_facet Kim, Mimi
Merrill, Joan T
Wang, Cuiling
Viswanathan, Shankar
Kalunian, Ken
Hanrahan, Leslie
Izmirly, Peter
author_sort Kim, Mimi
collection PubMed
description OBJECTIVE: A common problem in clinical trials is missing data due to participant dropout and loss to follow-up, an issue which continues to receive considerable attention in the clinical research community. Our objective was to examine and compare current and alternative methods for handling missing data in SLE trials with a particular focus on multiple imputation, a flexible technique that has been applied in different disease settings but not to address missing data in the primary outcome of an SLE trial. METHODS: Data on 279 patients with SLE randomised to standard of care (SoC) and also receiving mycophenolate mofetil (MMF), azathioprine or methotrexate were obtained from the Lupus Foundation of America-Collective Data Analysis Initiative Database. Complete case analysis (CC), last observation carried forward (LOCF), non-responder imputation (NRI) and multiple imputation (MI) were applied to handle missing data in an analysis to assess differences in SLE Responder Index-5 (SRI-5) response rates at 52 weeks between patients on SoC treated with MMF versus other immunosuppressants (non-MMF). RESULTS: The rates of missing data were 32% in the MMF and 23% in the non-MMF groups. As expected, the NRI missing data approach yielded the lowest estimated response rates. The smallest and least significant estimates of differences between groups were observed with LOCF, and precision was lowest with the CC method. Estimated between-group differences were magnified with the MI approach, and imputing SRI-5 directly versus deriving SRI-5 after separately imputing its individual components yielded similar results. CONCLUSION: The potential advantages of applying MI to address missing data in an SLE trial include reduced bias when estimating treatment effects, and measures of precision that properly reflect uncertainty in the imputations. However, results can vary depending on the imputation model used, and the underlying assumptions should be plausible. Sensitivity analysis should be conducted to demonstrate robustness of results, especially when missing data proportions are high.
format Online
Article
Text
id pubmed-6784820
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67848202019-10-24 SLE clinical trials: impact of missing data on estimating treatment effects Kim, Mimi Merrill, Joan T Wang, Cuiling Viswanathan, Shankar Kalunian, Ken Hanrahan, Leslie Izmirly, Peter Lupus Sci Med Clinical Trials and Drug Discovery OBJECTIVE: A common problem in clinical trials is missing data due to participant dropout and loss to follow-up, an issue which continues to receive considerable attention in the clinical research community. Our objective was to examine and compare current and alternative methods for handling missing data in SLE trials with a particular focus on multiple imputation, a flexible technique that has been applied in different disease settings but not to address missing data in the primary outcome of an SLE trial. METHODS: Data on 279 patients with SLE randomised to standard of care (SoC) and also receiving mycophenolate mofetil (MMF), azathioprine or methotrexate were obtained from the Lupus Foundation of America-Collective Data Analysis Initiative Database. Complete case analysis (CC), last observation carried forward (LOCF), non-responder imputation (NRI) and multiple imputation (MI) were applied to handle missing data in an analysis to assess differences in SLE Responder Index-5 (SRI-5) response rates at 52 weeks between patients on SoC treated with MMF versus other immunosuppressants (non-MMF). RESULTS: The rates of missing data were 32% in the MMF and 23% in the non-MMF groups. As expected, the NRI missing data approach yielded the lowest estimated response rates. The smallest and least significant estimates of differences between groups were observed with LOCF, and precision was lowest with the CC method. Estimated between-group differences were magnified with the MI approach, and imputing SRI-5 directly versus deriving SRI-5 after separately imputing its individual components yielded similar results. CONCLUSION: The potential advantages of applying MI to address missing data in an SLE trial include reduced bias when estimating treatment effects, and measures of precision that properly reflect uncertainty in the imputations. However, results can vary depending on the imputation model used, and the underlying assumptions should be plausible. Sensitivity analysis should be conducted to demonstrate robustness of results, especially when missing data proportions are high. BMJ Publishing Group 2019-10-03 /pmc/articles/PMC6784820/ /pubmed/31649825 http://dx.doi.org/10.1136/lupus-2019-000348 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Clinical Trials and Drug Discovery
Kim, Mimi
Merrill, Joan T
Wang, Cuiling
Viswanathan, Shankar
Kalunian, Ken
Hanrahan, Leslie
Izmirly, Peter
SLE clinical trials: impact of missing data on estimating treatment effects
title SLE clinical trials: impact of missing data on estimating treatment effects
title_full SLE clinical trials: impact of missing data on estimating treatment effects
title_fullStr SLE clinical trials: impact of missing data on estimating treatment effects
title_full_unstemmed SLE clinical trials: impact of missing data on estimating treatment effects
title_short SLE clinical trials: impact of missing data on estimating treatment effects
title_sort sle clinical trials: impact of missing data on estimating treatment effects
topic Clinical Trials and Drug Discovery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784820/
https://www.ncbi.nlm.nih.gov/pubmed/31649825
http://dx.doi.org/10.1136/lupus-2019-000348
work_keys_str_mv AT kimmimi sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT merrilljoant sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT wangcuiling sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT viswanathanshankar sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT kalunianken sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT hanrahanleslie sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects
AT izmirlypeter sleclinicaltrialsimpactofmissingdataonestimatingtreatmenteffects